>
Pete Hegseth Says AI Is God-Given 'Manifest Destiny'
Dust Off The Shovels: Quick Burst Of Snow Targets Mid-Atlantic, I-95 Corridor
The Soul vs. The Machine: A preview of the AI-ruled future where humans are obsolete
This tiny dev board is packed with features for ambitious makers
Scientists Discover Gel to Regrow Tooth Enamel
Vitamin C and Dandelion Root Killing Cancer Cells -- as Former CDC Director Calls for COVID-19...
Galactic Brain: US firm plans space-based data centers, power grid to challenge China
A microbial cleanup for glyphosate just earned a patent. Here's why that matters
Japan Breaks Internet Speed Record with 5 Million Times Faster Data Transfer
Advanced Propulsion Resources Part 1 of 2
PulsarFusion a forward-thinking UK aerospace company, is pushing the boundaries of space travel...
Dinky little laser box throws big-screen entertainment from inches away
'World's first' sodium-ion flashlight shines bright even at -40 ºF

Two adults with leukaemia have been in remission since 2010 after Car-T therapy.
It involves removing blood and genetically modifying its white cells so they target cancer.
The resulting Car-T cells are re-injected in a type of immunotherapy which uses the body's immune system to attack tumours.
Levels of the cells in the two cured patients remain high.
Dr Carl June, of the University of Pennsylvania, US, said: "Based on these results, we can conclude that Car-T cells can cure leukaemia.
"These cells continued to demonstrate tumour-killing characteristics."
Patient Doug Olsen said medics could not find any cancer after a few weeks. He said: "I knew the doctors weren't sure but I was pretty convinced that I was done with cancer."
The NHS offers Car-T to some children with leukaemia and adults with lymphoma.
It warns the therapy can make the immune system over-react or trigger side effects such as fever, vomiting or breathing difficulties.